lunes, 6 de junio de 2016

Endocrine Disrupting Chemicals : Pesticides and Plastics lobby to win over EU Commission - TruePublica

Endocrine Disrupting Chemicals : Pesticides and Plastics lobby to win over EU Commission - TruePublica

 

Endocrine Disrupting Chemicals : Pesticides and Plastics lobby to win over EU Commission

17th May 2016 / EU
Endocrine Disrupting Chemicals: Will Pesticides and Plastics lobby win over the EU Commission

 A Busy May For Professor Boobis by Corporate Europe Observatory
– This May is dense on the EU chemicals regulation front. Crunch time
for two major files: the European Commission needs to publish the
identification criteria for endocrine disrupting chemicals, and together
with EU States must decide how, or not, renew the market approval of
glyphosate, an herbicide produced and defended by Monsanto. Last week,
the Professor Alan Boobis happened to be involved in both.




The “Concerned Toxicologists for Better Science and Regulation” meet EU Health & Food Safety Commissioner














An expert in regulatory toxicology from the UK’s Imperial College, Alan Boobis has had a long scientific and regulatory career.
He has published more than two hundred scientific papers and has
belonged to several expert panels in EU and global public regulatory
authorities. He also is a vice-president of ILSI Europe, the European
branch of one of the largest food industry lobby groups in the world,
the International Life Sciences Institute,
funded by corporations such as Monsanto, BASF, Coca-Cola, Kraft, and
McDonald’s. The conflicts of interest at the European Food Safety
Authority (EFSA) involving this lobby group triggered a scandal in 2012
which cost the agency a six month postponement of its budget approval by
the European Parliament. Boobis refused to leave ILSI in 2012 and as a
consequence could not be reappointed on a panel at EFSA afterwards.


ILSI organises work streams that try to replicate and anticipate
EFSA’s as well as other regulatory agencies’ in order to influence them.
The idea is to bring together scientists from these agencies, academia,
industry, and the public sector to work in a spirit of ‘partnership’
but on priorities defined by industry. A project Boobis was recently
involved in at an ILSI offshoot (HESI) is calledRISK21,
a wide-consulting initiative to propose methodologies for
“exposure-driven” (therefore not hazard-driven, we’ll come back to that
later) public risk assessments, which he led together with a scientist
from Syngenta, Timothy Pastor.


It was almost a consensus


The definition of criteria to identify endocrine disrupting chemicals (EDCs) is absolutely key to resolving the long battle to regulate them at the EU level. These scientific criteria should have been in place by December 2013, but heavy industry lobbying
threw a spanner in the works: certain chemicals identified as EDCs
would need to be banned. Protestations by NGOs and a court case by
member states followed. The European Commission is now expected to
publish these identification criteria before summer – indeed many
lobbying battles are first and foremost about definitions. In this case,
doses.


A strategy industry has used here to try to delay or halt regulation
has been to amplify a conflict in the scientific community. In this
case, it supports toxicologists who defend the time-tested approach that
toxicity primarily depends on the dose, but against endocrine
specialists who explain that this paradigm is not operational in their
field since the hormonal system does not work with a proportional
response between dose and effects, that identification criteria must be
broader and that the determination of ‘no observed adverse effect ‘
thresholds, a strict condition for authorisation, is in certain cases
impossible. Meaning a ban.


The idea has quite logically had the chemicals, pesticides, and
plastics industry up in arms. Their strategy has been to impose
‘potency’ as only cut-off criterion for identifying endocrine disruptors
– which would allow many EDCs to remain on the market. But to do this
they had to provide as much as possible of a credible “scientific
opposition” to keep uncertainty high.


A breakthrough to a conflict of several years between the two ‘camps’
was thought to have been reached some weeks ago, when both came
together in Berlin in April 2016 at a meeting facilitated by the German
Federal Risk Assessment Institute (BfR). The purpose of the meeting,
moderated by Anne Glover, the former Chief Scientific Adviser of the
European Commission (who had already facilitated such a discussion in
2013), was to elaborate together a consensus statement
on the state of knowledge and ignorance on the matter. This statement,
importantly, explained that “potency is not relevant for identification
of a compound as an endocrine disruptor” and that it was only an
“important factor for consideration during the characterization of the
hazards of endocrine disruptors.”